Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations

Transplantation

Volumn 92, Issue 3, 2011, Pages 267-270

  Planitzer, Christina B ^a   Saemann, Marcus D ^b   Gajek, Hartwig ^a   Farcet, Maria R ^a   Kreil, Thomas R ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cytomegalovirus; Immunoglobulins; Intravenous; Neutralization assays; Prophylaxis; Transplantation

Indexed keywords

GG'LQD; GG'SD; HYPERIMMUNE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; MISOPROSTOL; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; NEUTRALIZATION TESTS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 79961023607     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318224115e     Document Type: Article

References (21)

1. Razonable RR. Cytomegalovirus infection after liver transplantation: Current concepts and challenges. World J Gastroenterol 2008; 14: 4849.
2. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect 2007; 13: 953.
3. Adler SP, Nigro G. Findings and conclusions fromCMVhyperimmune globulin treatment trials. J Clin Virol 2009; 46(suppl 4): S54.
4. Chehimi J, Peppard J, Emanuel D. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: An in vitro comparison of currently available and previously effective immune globulins. Bone Marrow Transplant 1987; 2: 395.
5. Gupta CK, Leszczynski J, Gupta RK, et al. IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities. Biologicals 1996; 24: 117.
6. Oxelius VA. Immunoglobulin G (IgG) subclasses and human disease. Am J Med 1984; 76: 7.
7. Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 2010; 67: 1417.
8. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renaltransplant recipients. N Engl J Med 1987; 317: 1049.
9. Kocher AA, Bonaros N, Dunkler D, et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 2003; 22: 250.
10. Falagas ME, Snydman DR, Ruthazer R, et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997; 11: 432.
11. Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12.
12. Opelz G, Doehler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
13. Opelz G, Daniel V, Naujokat C, et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: A multicentre retrospective analysis. Lancet Oncol 2007; 8: 212.
14. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: The national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010; 50: 1439.
15. Teschner W, Butterweck HA, Auer W, et al. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-ofthe-art process. Vox Sang 2007; 92: 42.
16. Audet S, Virata-Theimer ML, Beeler JA, et al. Measles-virus-neutralizing antibodies in intravenous immunoglobulins. J Infect Dis 2006; 194: 781.
17. Food and Drug Administration. Vaccines, blood&biologics: Biological product shortages. Available at: http://www.fda.gov/BiologicsBlood Vaccines/SafetyAvailability/Shortages/default.htm. Accessed August 2010.
18. Gilljam G, Wahren B. Properties of IgG subclasses to human cytomegalovirus. J Virol Methods 1989; 25: 139.
19. Beck OE. Distribution of virus antibody activity among human IgG subclasses. Clin Exp Immunol 1981; 43: 626.
20. Hofmeister Y, Planitzer CB, Farcet MR, et al. Human IgG subclasses: In vitro Neutralization of and in vivo protection against West Nile virus. J Virol 2010; 85: 1896.
21. Planitzer CB, Modrof J, Yu MY, et al. West Nile virus infection in plasma of blood and plasma donors, United States. Emerg Infect Dis 2009; 15: 1668.